Gilead Faces Challenges In HCV, But Competitors Would Switch Places
Merck is pursuing a patient-access strategy in HCV with newly approved Zepatier, while AbbVie is acknowledging lower-than-projected 2015 sales for Viekira Pak but expressing optimism about competing in the space.
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?